Welcome to our dedicated page for Citius Pharmaceuticals news (Ticker: CTXR), a resource for investors and traders seeking the latest updates and insights on Citius Pharmaceuticals stock.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company focused on first-in-class critical care products and holds a majority interest in Citius Oncology, Inc. News about CTXR often centers on regulatory milestones, clinical progress, and financing activities that support the development and commercialization of its therapies.
Recent company communications emphasize the FDA approval of LYMPHIR (denileukin diftitox-cxdl) for adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy, and the subsequent U.S. commercial launch executed by Citius Oncology. CTXR news also highlights the late-stage status of Mino-Lok, a catheter lock solution for catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for hemorrhoid relief, along with completed pivotal and Phase 2b trials.
Investors following CTXR can expect updates on capital raises such as registered direct offerings and warrant issuances, which the company states are intended to fund the commercial launch of LYMPHIR, regulatory and milestone payments, and broader development initiatives. Filings and press releases also describe ongoing engagement with the FDA regarding next steps for Mino-Lok and Halo-Lido.
This news feed aggregates press releases, regulatory disclosures, and other public announcements related to Citius Pharmaceuticals and its majority-owned oncology subsidiary. For those tracking CTXR, it provides a centralized view of developments across oncology, critical care, clinical trials, and corporate finance. Regular review of this page can help readers monitor how Citius Pharmaceuticals advances its portfolio and supports the commercialization of LYMPHIR through Citius Oncology.
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) has established the Citius ARDS Scientific Advisory Board to guide the development of its induced mesenchymal stem cells (iMSCs) for treating Acute Respiratory Distress Syndrome (ARDS), especially in COVID-19 patients. The board comprises experts like Dr. Michael A. Matthay, Dr. Mitchell M. Levy, and Dr. Lorraine B. Ware, all recognized leaders in critical care and clinical trials. CEO Myron Holubiak expressed confidence in their expertise to enhance clinical trial design and execution for iMSC therapy.
Citius Pharmaceuticals (Nasdaq: CTXR) announced its participation in the MoneyShow Accredited Investor Virtual Event from July 22-24, 2020. Chairman Leonard Mazur will provide updates on the company's developmental products during a live presentation scheduled for 10:40 AM ET on July 22. Attendees can interact with the company in real-time, and an archived webcast will be available post-event. Interested investors must register for the event at the provided link.
On July 14, 2020, Citius Pharmaceuticals (CTXR) announced the appointment of Myron S. Czuczman, M.D., as Chief Medical Officer and Executive Vice President. Dr. Czuczman, previously at Celgene, is expected to enhance Citius's development programs, particularly for iPSC-derived mesenchymal stem cell therapy targeting ARDS related to COVID-19. This appointment comes as the company advances Phase 3 trials for Mino-Lok® and prepares an IND for Mino-Wrap. Citius focuses on critical care pharmaceuticals, especially anti-infectives and cancer treatments.
Citius Pharmaceuticals (NASDAQ: CTXR) announced on July 10, 2020, that it has regained compliance with NASDAQ's minimum bid price requirements, allowing it to remain listed on the exchange. This compliance closure is significant for the company as it continues its focus on developing critical care and cancer treatment products. Citius specializes in proprietary formulations of previously-approved drugs, targeting unmet medical needs while mitigating development risks.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) announced that its CEO, Myron Holubiak, will be featured on TD Ameritrade Network's The Watch List on June 30, 2020, at 1:20 PM ET. The show will involve discussions on market-moving topics with industry experts. Holubiak has a strong background in pharmaceutical management, previously serving as president of Roche Laboratories. Citius focuses on critical care pharmaceutical products, including therapies for acute respiratory distress syndrome (ARDS), which affects many COVID-19 patients annually.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) announced that the FDA has provided feedback on its pre-investigational new drug (PIND) application for its induced mesenchymal stem cells (iMSCs) aimed at treating acute respiratory distress syndrome (ARDS) in COVID-19 patients. The FDA suggested that Citius could apply for fast track designation and outlined the chemistry, manufacturing, and control (CMC) requirements necessary for upcoming trials. The company plans to initiate an Investigational New Drug (IND) application under the Coronavirus Treatment Acceleration Program (CTAP) following the FDA's guidance.
Citius Pharmaceuticals (Nasdaq: CTXR) announced that CEO Myron Holubiak will present at the Life Sciences Investor Forum on June 25, 2020, at 11:00 AM ET. The presentation will provide updates on the Company’s ongoing Phase 3 trial for Mino-Lok® and the potential licensing of a novel stem cell therapy for ARDS in COVID-19 patients. Investors can participate and ask questions during the event, which will also be available via archived webcast.